Sugi Predict

Sugi Predict / Compounds / SCHEMBL64564

SCHEMBL64564

SCHEMBL64564

CC1CN(C(=O)OC(C)(C)C)CC(C)N1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.56
▸ USP2 O75604 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ DDB1 Q16531 1/20 0.43
▸ CRBN Q96SW2 1/20 0.43
▸ HPGD P15428 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ RECQL P46063 1/20 0.41
▸ EPHX1 P07099 1/20 0.41
▸ MAPT P10636 2/20 0.40
▸ THRB P10828 1/20 0.40
▸ NAMPT P43490 1/20 0.40
▸ CHRM2 P08172 1/20 0.40
▸ CHRM1 P11229 1/20 0.40
▸ CHRM3 P20309 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ RORC P51449 1/20 0.39
▸ EPHX2 P34913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29165922 1.00 NR1H2 (0.56) NR1H2USP2SMN1; SMN2DDB1CRBN
SCHEMBL1005767 1.00 NR1H2 (0.56) NR1H2USP2SMN1; SMN2DDB1CRBN
SCHEMBL64563 1.00 NR1H2 (0.56) NR1H2USP2SMN1; SMN2DDB1CRBN
SCHEMBL1005536 1.00 NR1H2 (0.56) NR1H2USP2SMN1; SMN2DDB1CRBN
Hydrochloric Acid SCHEMBL28576538 0.98 NR1H2 (0.54) NR1H2USP2SMN1; SMN2DDB1CRBN
SCHEMBL25669757 0.90 NR1H2 (0.50) NR1H2USP2SMN1; SMN2DDB1CRBN
SCHEMBL28455854 0.88 NR1H2 (0.49) NR1H2USP2SMN1; SMN2DDB1CRBN
SCHEMBL27256391 0.88 NR1H2 (0.49) NR1H2USP2SMN1; SMN2DDB1CRBN
SCHEMBL22972577 0.87 NR1H2 (0.55) NR1H2USP2SMN1; SMN2DDB1CRBN
SCHEMBL30384932 0.87 NR1H2 (0.55) NR1H2USP2SMN1; SMN2DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 455 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104046246-B The chemical-mechanical planarization of tungsten-containing substrate 气体产品与化学公司 2016-06-15 — — CN claimed
EP-2589601-B1 COMPOUND FOR INHIBITING TYPE 5 PHOSPHODIESTERASE AND PREPARATION METHOD THEREOF SUZHOU MAIDIXIAN PHARMACEUTICAL INC (CN) 2015-09-09 — — EP claimed
US-8859565-B2 Compound for inhibiting type 5 phosphodiesterase and preparation method thereof ZHANG NAN (CN) 2014-10-14 — — US claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 — — US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 — — EP claimed
US-20130116265-A1 COMPOUND FOR INHIBITING TYPE 5 PHOSPHODIESTERASE AND PREPARATION METHOD THEREOF ZHANG NAN (CN) 2013-05-09 — — US claimed
EP-2589601-A1 COMPOUND FOR INHIBITING TYPE 5 PHOSPHODIESTERASE AND PREPARATION METHOD THEREOF Suzhou Maidixian Pharmaceutical Inc. (CN) 2013-05-08 — — EP claimed
CN-101891747-B Compound for inhibiting type 5 phosphodiesterase and preparation method thereof NAN ZHANG 2012-04-25 — — CN claimed
CN-101891747-A Compound capable of inhibiting phosphodiesterase type 5 and preparation method SUZHOU MAIDIXIAN MEDICINE SCIENCE & TECHNOLOGY CO LTD 2010-11-24 — — CN claimed
EP-3433239-B1 SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) 2026-05-27 — — EP disclosed
US-20250381187-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. (US) 2025-12-18 — — US disclosed
US-20250362134-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. (US) 2025-11-27 — — US disclosed
WO-2025228900-A1 ARYLAMIDE SUBSTITUTED INDAZOLES AND THE USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-11-06 — — WO disclosed
US-12440491-B2 KRAS G12C inhibitors and methods of using the same AMGEN INC. (US) 2025-10-14 — — US disclosed
EP-0891332-A1 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES PFIZER INC. (US) 1999-01-20 — — EP disclosed
US-5686610-A Pyridyl piperazine compound PHARMACIA & UPJOHN COMPANY (US) 1997-11-11 — — US disclosed
WO-1997040051-A1 FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-10-30 — — WO disclosed
WO-1997036871-A1 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES PFIZER INC. (US) 1997-10-09 — — WO disclosed
US-5599930-A Substituted indoles as anti-AIDS pharmaceuticals THE UPJOHN COMPANY (US) 1997-02-04 — — US disclosed
WO-1993001181-A1 SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICALS THE UPJOHN COMPANY (US) 1993-01-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250381187-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME KRAS, NRAS, HRAS NR1H2 2595/4885USP2 1042/4885SMN1; SMN2 3173/4885
US-12440491-B2 KRAS G12C inhibitors and methods of using the same KRAS, NRAS, HRAS NR1H2 2595/4885USP2 1042/4885SMN1; SMN2 3173/4885
US-20130116265-A1 COMPOUND FOR INHIBITING TYPE 5 PHOSPHODIESTERASE AND PREPARATION METHOD THEREOF PDE5A, PDE3B, PDE3A NR1H2 2097/4885USP2 3231/4885SMN1; SMN2 3474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.